Diagnostische Wertigkeit der ¹⁸F-FDG-PET und MRT bei frühkindlicher Histiozytose

Zusammenfassung

Es wird in diesem Übersichtsartikel die diagnostische Wertigkeit der ¹⁸F-Fluorodeoxyglucose-Positronenemissionstomografie (¹⁸F-FDG-PET) und Magnetresonanztomografie (MRT) für die Beurteilung der frühkindlichen Histiozytose dargestellt. Dabei werden Studien verglichen, die die Genauigkeit der ¹⁸F-FDG-PET und MRT untersuchten. Es zeigt sich ein Vorteil der ¹⁸F-FDG-PET in der Beurteilung der Tumoraktivität nach Chemotherapie. Die MRT zeigt eine höhere Sensitivität bei der Primärdiagnostik sowie bei der Beurteilung des intrazerebralen Befalls. Die kombinierte PET/MRT hat das Potenzial, die Vorteile beider Modalitäten in einem Untersuchungsdurchlauf zu verbinden.

Abstract

To analyze the diagnostic value of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) and magnetic resonance imaging for the evaluation of paediatric Langerhans cell histiocytosis. Results from different studies on the diagnostic accuracy of both modalities are compared. Our analysis suggests an important role of ¹⁸F-FDG PET for lesion follow-up after chemotherapy. MRI showed a higher sensitivity at primary diagnosis and is indispensable for evaluation of brain involvement. Simultaneous whole body PET/MRI acquisition may have the potential to combine the advantages of both modalities in one examination.

Schlüsselwörter

Histiozytose - FDG - PET - MRT - Wertigkeit

Key words

histiocytosis - FDG - PET - MRI - diagnostic value

• Literatur

• 1 Azouz EM, Saigal G, Rodriguez MM et al. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol 2005; 35: 103-115
• 2 Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDG-PET in the evaluation of Langerhans’ cell histiocytosis: preliminary findings. Pediatr Radiol 2003; 33: 598-602
• 3 Blum R, Seymour JF, Hicks RJ. Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma 2002; 43: 2155-2157
• 4 Buchler T, Cervinek L, Belohlavek O et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer 2005; 44: 286-288
• 5 Drzezga A, Souvatzoglou M, Eiber M et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012; 53: 845-855 [pii]10.2967/jnumed.111.098608
• 6 Gadner H, Grois N, Arico M et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728-734 [pii] 10.1067/mpd.2001.111331
• 7 Gadner H, Grois N, Potschger U et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111: 2556-2562 [pii] 10.1182/blood-2007-08-106211
• 8 Grois N, Fahrner B, Arceci RJ et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156: 873-881 81 e1 [pii] 10.1016/j.jpeds.2010.03.001
• 9 Grois N, Potschger U, Prosch H et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228-233
• 10 Grois N, Tsunematsu Y, Barkovich AJ et al. Central nervous system disease in Langerhans cell histiocytosis. Br J Cancer Suppl 1994; 23: S24-S28
• 11 Goo HW, Yang DH, Ra YS et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006; 36: 1019-1031
• 12 Hoover KB, Rosenthal DI, Mankin H. Langerhans cell histiocytosis. Skeletal Radiol 2007; 36: 95-104
• 13 Kaste SC, Rodriguez-Galindo C, McCarville ME et al. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol 2007; 37: 615-622
• 14 Kellenberger CJ, Epelman M, Miller SF et al. Fast STIR whole-body MR imaging in children. Radiographics 2004; 24: 1317-1330 24/5/1317 [pii]
• 15 Kilborn TN, Teh J, Goodman TR. Paediatric manifestations of Langerhans cell histiocytosis: a review of the clinical and radiological findings. Clin Radiol 2003; 58: 269-278 [pii]
• 16 Krajicek BJ, Ryu JH, Hartman TE et al. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009; 135: 1542-1549 [pii]10.1378/chest.08-1899
• 17 Lee HJ, Ahn BC, Lee SW et al. The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. Ann Nucl Med
• 18 Mentzel HJ, Kentouche K, Sauner D et al. Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. Eur Radiol 2004; 14: 2297-2302
• 19 Meyer JS, De Camargo B. The role of radiology in the diagnosis and follow-up of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 307-326
• 20 Minkov M, Grois N, Heitger A et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002; 39: 581-585
• 21 Mueller WP, Melzer HI, Schmid I et al. The diagnostic value of ¹⁸F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging 2013; 40: 356-363
• 22 Ohno Y, Koyama H, Yoshikawa T et al. Pulmonary magnetic resonance imaging for airway diseases. J Thorac Imaging 2011; 26: 301-316 00005382-201111000-00007 [pii]
• 23 Pavlik M, Bloom DA, Ozgonenel B et al. Defining the role of magnetic resonance imaging in unifocal bone lesions of langerhans cell histiocytosis. J Pediatr Hematol Oncol 2005; 27: 432-435 [pii]
• 24 Phillips M, Allen C, Gerson P et al. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009; 52: 97-101
• 25 Schmidt S, Eich G, Geoffray A et al. Extraosseous langerhans cell histiocytosis in children. Radiographics 2008; 28: 707-726 quiz 910-9111 [pii]10.1148/rg.283075108